Oncologists love pushing the limits of what is possible for our patients. To celebrate this and the 20th episode of Oncology for the Inquisitive Mind, Michael and Josh explore the heights of pioneering treatment for early-stage triple-negative breast cancer (TNBC). A notoriously resistant cancer with no known targetable lesions that affect younger women on average, The BrighTNess trial, Keynote 522 and Create-X show just how far the treatment landscape has changed in the last five years.
Tune into our final episode for the year! We will return in early 2023 with more content, interviews and hilarious banter.
On a final note, Dr Michael Fernando has been admitted to the Royal Australian College of Physicians (RACP), the equivalent of being board certified! Michael has completed this arduous training and is now a fully-fledged Medical Oncologist! Do not distress listeners. Despite no longer being a trainee, Michael will continue on as presenter and host extraordinaire for this podcast.
Links to studies discussed in this episode (subscription may be required):
BrighTNess trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30111-6/fulltext
Keynote 522: https://www.nejm.org/doi/full/10.1056/NEJMoa1910549
Create-X: https://www.nejm.org/doi/full/10.1056/NEJMoa1612645
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
","author_name":"Michael Fernando and Josh Hurwitz"}